Recon: Express Scripts sues FTC over PBM report; Neuralink brain implant nabs breakthrough device designation

• Express Scripts sues FTC over a ‘biased’ report about pharmacy benefit managers (STAT) (Reuters)
• Philip Morris to sell Vectura for $198 mln after health shift criticism (Reuters)
• US Senate set to vote again on IVF bill after Trump's pledge of support (Reuters)
• US FDA approves Eli Lilly's drug for eczema (Reuters)
• Musk's Neuralink receives FDA's breakthrough device tag for brain implant (Reuters)
• US Senator Sanders says generic drugmakers could sell Ozempic for less than $100/month (Reuters)

• WHO pandemic threat director: Here’s what needs to happen to combat mpox (STAT)
• After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do (STAT)
• Sun, surprises and new summits at Europe’s biggest cancer conference (Endpoints)
• How To Transfer Surveillance Oversight For IVDs From One EU Notified Body To Another (MedTech Insight)
• EU Pharma Calls For Better Metrics On True Impact Of Clinical Trial Disclosure (Pink Sheet)
• Geopolitics, US BIOSECURE: Pharma Looks To Redistribute CDMO Footprint (Pink Sheet)
• EU Decision Time For Orphan Drugs Marstacimab, Serplulimab And Mirvetuximab Soravtansine (Pink Sheet)
• Antibiotic-resistance deaths to surge from 2025-2050, study says (Reuters)

• FDA formalizes protocol for international cancer trials (STAT)
• 11 people shaping psychedelics drug development (STAT)
• Genentech, a biotech with a storied past, confronts new turbulence in the present (STAT)
• Emmet Stephenson gives $150M to City of Hope for pancreatic cancer, creating million-dollar research prize (STAT)
• Bad trip: How culture conflict and a need for cash nearly broke Lykos (Endpoints)
• Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers (Endpoints)
• Nura Bio raises $68M for clinical tests of SARM1 inhibitor to potentially slow or prevent nerve degeneration (Endpoints)
• Coherus warns of limited cancer drug supply due to third-party ‘capacity constraints’ (Endpoints)
• Capricor expands DMD pact with Nippon Shinyaku; AbbVie’s new eye deal (Endpoints)
• After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3 (Endpoints)
• 23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team (Endpoints)
• Click’s Digital Therapeutic Shown To Enhance Clinical Benefit Of Migraine Drugs In Pivotal Trial (MedTech Insight)

• Most cardiovascular devices with serious safety recalls aren’t tested in patients (STAT)
• What pharma companies and insurers think about Medicare’s plan to cover digital treatments (STAT)
• A documentary film asks: Can health systems improve patient safety by embracing new tech? (STAT)
• J&J Versus Auris: Robotics Fallout With Big Implications For M&A (MedTech Insight)
• Exact Sciences Announces Early Results From Colorectal Cancer Blood Test At ESMO 2024 (MedTech Insight)
• MDIC Head Andy Fish On Driving Positive Change In The Medtech Ecosystem (MedTech Insight)

• End the ‘forced swim test’ on mice for antidepressant research (STAT)
• How insurers are covering Humira and copycat medicines (STAT)
• J&J gets $260 million talc verdict overturned in Oregon, new trial ordered (Reuters)
• Drug Pricing And The US Presidential Campaign: A Non-Issue? (Pink Sheet)